KR102019000B1 - 질소 스캐빈징 약물들의 치료학적 모니터링 방법들 - Google Patents

질소 스캐빈징 약물들의 치료학적 모니터링 방법들 Download PDF

Info

Publication number
KR102019000B1
KR102019000B1 KR1020187020761A KR20187020761A KR102019000B1 KR 102019000 B1 KR102019000 B1 KR 102019000B1 KR 1020187020761 A KR1020187020761 A KR 1020187020761A KR 20187020761 A KR20187020761 A KR 20187020761A KR 102019000 B1 KR102019000 B1 KR 102019000B1
Authority
KR
South Korea
Prior art keywords
ammonia
fasting
dose
levels
uln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187020761A
Other languages
English (en)
Korean (ko)
Other versions
KR20180085823A (ko
Inventor
브루스 샤르슈미트
마수드 모크타라니
Original Assignee
호라이즌 쎄라퓨틱스, 엘엘씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102019000(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 호라이즌 쎄라퓨틱스, 엘엘씨. filed Critical 호라이즌 쎄라퓨틱스, 엘엘씨.
Publication of KR20180085823A publication Critical patent/KR20180085823A/ko
Application granted granted Critical
Publication of KR102019000B1 publication Critical patent/KR102019000B1/ko
Assigned to 임메디카 파마 에이비 reassignment 임메디카 파마 에이비 권리의 전부이전등록 Assignors: 호라이즌 쎄라퓨틱스, 엘엘씨.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y10T436/175383—Ammonia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
KR1020187020761A 2011-09-30 2012-03-09 질소 스캐빈징 약물들의 치료학적 모니터링 방법들 Active KR102019000B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161542100P 2011-09-30 2011-09-30
US61/542,100 2011-09-30
US201161564668P 2011-11-29 2011-11-29
US61/564,668 2011-11-29
PCT/US2012/028620 WO2013048558A2 (en) 2011-09-30 2012-03-09 Methods of therapeutic monitoring of nitrogen scavenging drugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147011146A Division KR20140094517A (ko) 2011-09-30 2012-03-09 질소 스캐빈징 약물들의 치료학적 모니터링 방법들

Publications (2)

Publication Number Publication Date
KR20180085823A KR20180085823A (ko) 2018-07-27
KR102019000B1 true KR102019000B1 (ko) 2019-09-05

Family

ID=47892277

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187020761A Active KR102019000B1 (ko) 2011-09-30 2012-03-09 질소 스캐빈징 약물들의 치료학적 모니터링 방법들
KR1020147011146A Ceased KR20140094517A (ko) 2011-09-30 2012-03-09 질소 스캐빈징 약물들의 치료학적 모니터링 방법들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147011146A Ceased KR20140094517A (ko) 2011-09-30 2012-03-09 질소 스캐빈징 약물들의 치료학적 모니터링 방법들

Country Status (25)

Country Link
US (21) US8404215B1 (enExample)
EP (2) EP3263102A1 (enExample)
JP (2) JP6073898B2 (enExample)
KR (2) KR102019000B1 (enExample)
CN (2) CN104039358A (enExample)
AU (2) AU2012316750B2 (enExample)
BR (1) BR112014007357B1 (enExample)
CA (1) CA2850391A1 (enExample)
CL (1) CL2014000783A1 (enExample)
CY (1) CY1119028T1 (enExample)
DK (1) DK2760479T3 (enExample)
ES (1) ES2629859T3 (enExample)
HR (1) HRP20171063T1 (enExample)
HU (1) HUE035220T2 (enExample)
IL (2) IL231732A (enExample)
LT (1) LT2760479T (enExample)
MX (2) MX366197B (enExample)
PL (1) PL2760479T3 (enExample)
PT (1) PT2760479T (enExample)
RS (1) RS56196B1 (enExample)
SG (1) SG11201400781TA (enExample)
SI (1) SI2760479T1 (enExample)
SM (1) SMT201700321T1 (enExample)
WO (1) WO2013048558A2 (enExample)
ZA (1) ZA201401851B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
EP3019074B1 (en) * 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
PL2986325T3 (pl) 2013-10-14 2020-03-31 Immedica Pharma Ab Sposoby leczenia zaburzenia cyklu mocznikowego
JP2017501972A (ja) 2013-11-14 2017-01-19 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． トリグリセリドの固体組成物及びその使用
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN108430514B (zh) 2015-10-29 2023-11-03 约翰霍普金斯大学 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
WO2017147193A1 (en) * 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JP6752748B2 (ja) 2017-03-30 2020-09-09 住友重機械工業株式会社 減速装置
EP3649474A1 (en) * 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
US12139546B2 (en) * 2017-08-22 2024-11-12 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
WO2022011061A1 (en) * 2020-07-07 2022-01-13 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100008859A1 (en) 2008-04-29 2010-01-14 Scharschmidt Bruce Methods of treatment using ammonia-scavenging drugs

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004595A (en) 1911-05-25 1911-10-03 Sargents Sons Corp C G Carrier for washing-bowls.
US1018300A (en) 1911-06-12 1912-02-20 John Davidson Condensing steam-engine.
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
WO1996024571A1 (en) 1995-02-07 1996-08-15 Brusilow Saul W Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
DE19805854C1 (de) 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
IT1317073B1 (it) 2000-12-12 2003-05-26 Mini Ricerca Scient Tecnolog Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US6825384B1 (en) 2004-01-29 2004-11-30 The Nutrasweet Company Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
PT2319581E (pt) * 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
GB2465250B (en) 2008-08-29 2011-01-26 Ucyclyd Pharma Inc Dosing and monitoring patients on nitrogen-scavenging drugs
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
JP5577341B2 (ja) 2008-08-29 2014-08-20 ハイペリオン セラピューティクス， インコーポレイテッド アンモニア捕捉薬を使用する処置方法
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
EP2594550B1 (en) 2010-07-16 2016-10-12 Tohoku University Method for oxidizing alcohols
JP6049619B2 (ja) 2010-08-31 2016-12-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
BR112014026138A2 (pt) 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
CN103304402B (zh) 2013-05-24 2015-04-22 苏州诚和医药化学有限公司 一种制备4-苯-1-丁酸的方法
EP3019074B1 (en) 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
PL2986325T3 (pl) 2013-10-14 2020-03-31 Immedica Pharma Ab Sposoby leczenia zaburzenia cyklu mocznikowego
IN2013MU03442A (enExample) 2013-10-30 2015-07-17 Lupin Ltd
ES2748294T3 (es) 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
WO2017147193A1 (en) 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100008859A1 (en) 2008-04-29 2010-01-14 Scharschmidt Bruce Methods of treatment using ammonia-scavenging drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mol Genet Metab. 2011.08., Vol. 103, pp 323-329.

Also Published As

Publication number Publication date
MX2019006900A (es) 2019-09-04
US9962359B2 (en) 2018-05-08
US20180055807A1 (en) 2018-03-01
US20190125713A1 (en) 2019-05-02
EP2760479B1 (en) 2017-05-03
JP2014532179A (ja) 2014-12-04
US8404215B1 (en) 2013-03-26
CY1119028T1 (el) 2018-01-10
US20180021293A1 (en) 2018-01-25
EP2760479A4 (en) 2015-08-26
HUE035220T2 (hu) 2018-05-02
US9254278B2 (en) 2016-02-09
AU2012316750A1 (en) 2014-03-27
IL231732A0 (en) 2014-05-28
US20150335605A1 (en) 2015-11-26
ZA201401851B (en) 2018-05-30
IL231732A (en) 2017-09-28
CN107271696A (zh) 2017-10-20
US20180263949A1 (en) 2018-09-20
US10183006B2 (en) 2019-01-22
US20210000784A1 (en) 2021-01-07
US20180021291A1 (en) 2018-01-25
US20180263948A1 (en) 2018-09-20
US20160199333A1 (en) 2016-07-14
SMT201700321T1 (it) 2017-09-07
US20160199334A1 (en) 2016-07-14
US10183005B2 (en) 2019-01-22
US20180221325A1 (en) 2018-08-09
US10183002B2 (en) 2019-01-22
US9326966B2 (en) 2016-05-03
HRP20171063T1 (hr) 2017-10-06
US20160199332A1 (en) 2016-07-14
AU2012316750B2 (en) 2017-08-31
US10045958B1 (en) 2018-08-14
US20180221327A1 (en) 2018-08-09
EP3263102A1 (en) 2018-01-03
PT2760479T (pt) 2017-07-21
US9095559B2 (en) 2015-08-04
US20130210914A1 (en) 2013-08-15
ES2629859T3 (es) 2017-08-16
IL254134A0 (en) 2017-10-31
JP6425746B2 (ja) 2018-11-21
US10183004B2 (en) 2019-01-22
LT2760479T (lt) 2017-07-10
US20180235920A1 (en) 2018-08-23
SI2760479T1 (sl) 2017-07-31
US10045959B1 (en) 2018-08-14
US9962358B2 (en) 2018-05-08
BR112014007357A2 (pt) 2017-04-04
US20180221324A1 (en) 2018-08-09
WO2013048558A2 (en) 2013-04-04
CL2014000783A1 (es) 2015-01-16
US10617665B2 (en) 2020-04-14
US20160202240A1 (en) 2016-07-14
DK2760479T3 (en) 2017-07-17
JP2017067791A (ja) 2017-04-06
US20130085179A1 (en) 2013-04-04
KR20140094517A (ko) 2014-07-30
US20160081969A1 (en) 2016-03-24
MX2014003854A (es) 2014-10-17
KR20180085823A (ko) 2018-07-27
CA2850391A1 (en) 2013-04-04
AU2017251691A1 (en) 2017-11-09
US20180015064A1 (en) 2018-01-18
BR112014007357B1 (pt) 2022-12-06
PL2760479T3 (pl) 2017-09-29
JP6073898B2 (ja) 2017-02-01
WO2013048558A3 (en) 2014-04-03
CN104039358A (zh) 2014-09-10
MX366197B (es) 2019-06-25
RS56196B1 (sr) 2017-11-30
US20180221326A1 (en) 2018-08-09
EP2760479A2 (en) 2014-08-06
US9999608B2 (en) 2018-06-19
US10183003B2 (en) 2019-01-22
SG11201400781TA (en) 2014-04-28

Similar Documents

Publication Publication Date Title
US10617665B2 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
A302 Request for accelerated examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180718

Application number text: 1020147011146

Filing date: 20140425

PA0201 Request for examination
PA0302 Request for accelerated examination

Patent event date: 20180718

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181017

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190530

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190830

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190830

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220701

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220701

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230720

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240711

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250617

Start annual number: 7

End annual number: 7